^
    Back
    Association details:
    Biomarker:ALK L1198F
    Cancer:Non Small Cell Lung Cancer
    Drug:Xalkori (crizotinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    N Engl J Med
    Title:

    Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F

    Excerpt:
    This acquired L1198F mutation conferred resistance to lorlatinib, but unexpectedly restored sensitivity to crizotinib, a less potent and less selective first-generation inhibitor.
    DOI:
    10.1056/NEJMoa1508887